Library

Safety and Pharmacokinetics of HTL0018318, a Novel M Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects.

23 June 2021. doid: 10.1007/s40268-021-00352-5

Bakker C, van der Aart J, Labots G, Liptrot J, Cross DM, Klaassen ES, Dickinson S, Tasker T, Groeneveld GJ

View publication

HTL0018318 is a selective muscarinic M receptor partial agonist under development for the symptomatic treatment of dementias, including Alzheimer's disease. Clinically, HTL0018318 would likely be used alone or in conjunction with cholinesterase inhibitors (e.g. donepezil).

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact